Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Veracyte
AddedFeb 19, 2024
UpdatedJun 18, 2026
Veracyte

Veracyte

Public

Veracyte, Inc., based in South San Francisco, develops molecular oncology tests and provides diagnostic accuracy services.

HQ
South San Francisco, CA, US
Founded
2006
Overview
Compare
Fundraising
Employees
Website

Veracyte, Inc., founded in South San Francisco, focuses on developing molecular tests for oncology to enhance diagnostic accuracy. The company's mission is to provide exceptional cancer care through exceptional diagnostics. Veracyte offers a range of genomic classifiers, including the Afirma® Genomic Sequencing Classifier for thyroid cancer, Decipher® Prostate and Bladder Genomic Classifiers, Prosigna® Breast Cancer Assay, and Envisia® Genomic Classifier for interstitial lung disease (ILD). Their services target healthcare and molecular diagnostic companies across the United States.

Notable affiliations include the recent acquisition of C2i Genomics, expanding Veracyte's capabilities in precision oncology. Key achievements include the widespread adoption of their genomic classifiers, which have significantly improved diagnostic accuracy and patient outcomes in cancer care. Veracyte's impact is evident in its contribution to the early and precise diagnosis of various cancers, thereby enabling more effective treatment plans and improving overall patient care.

Veracyte - Quick Facts

When was Veracyte founded?

Veracyte was founded in 2006.

Where is Veracyte's headquarters located?

Veracyte's headquarters is located in South San Francisco, CA, US.

When was Veracyte's last funding round?

Veracyte's most recent funding round was for $550M (USD) in February 2021.

How much has Veracyte raised to-date?

As of Feb 5, 2021, Veracyte has raised a total of $681.3M (USD).

How many employees does Veracyte have?

Veracyte has 787 employees as of Feb 6, 2024.

Veracyte - Classification

Industry
  • Diagnostics
Ownership
  • Public
Technology
  • Biotech
  • Genomics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Oncology Tests
Tags
  • Healthcare
  • Healthtech
Unique IDs
  • ein: 205455398
  • secCik: 0001384101
  • ticker: VCYT
NAICS
  • 621000Ambulatory Health Care Services
  • 621500Medical and Diagnostic Laboratories
  • 621510Medical and Diagnostic Laboratories
  • 621511Medical Laboratories
  • 620000Health Care and Social Assistance
SIC
  • 8070Medical And Dental Laboratories
  • 8071Medical Laboratories
  • 8000Health Services
ISIC
  • 8690Other human health activities
Show 6 more industry codes
NAICS
  • 621512Diagnostic Imaging Centers
  • 623000Nursing and Residential Care Facilities
SIC
  • 6000Depository Institutions
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
ISIC
  • 7210Research and experimental development on natural sciences and engineering